Aneurysmal subarachnoid hemorrhage
Conditions
Interventions
pitavastatin
placebo
Sponsors
Hirosaki University Graduate School of Medicine, Department of Neurosurgery
1. Aomori City Hospital 2. The Medical Journal of Kuroishi City Hospital 3. Towada City Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Ruptured aneurysm was secured by clipping or coiling within 48 hours after the onset of SAH, and administration of pitavastatin or placebo was started within 72 hours after the onset of SAH. 3. SAH should be diffuse or localized thick subarachnoid clot on CT scan performed within 24 hours of SAH. 2. clinical grade evaluated by Hunt and Hess Grade was 1 to 4 before clipping or coiling.
Exclusion criteria
Exclusion criteria: 1. Pre-existing major hepatic, renal disease. 2. prior cerebral damage of past history of stroke or traumatic brain injury confirmed by CT scan. 3. focal neurological deficits on admission due to accompanying intracerebral clot. 4. current use of anti-platelet, anticoagulant agent and/or statins. 5. operative neurological deficits arisen due to clipping or coiling procedure. 6.drug allergy 7. pregnancy.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The primary efficacy end point is the onset of delayed ischemic neurologic deficits (DIND). | — |
Secondary
| Measure | Time frame |
|---|---|
| 1) angiographic vasospasm on digital subtraction angiography (DSA) 2) cerebral infarction due to cerebral vasospasm on CT scan 3) clinical outcome on the Glasgow Outcome Scale (GOS) at 3 months 4) adverse events | — |
Countries
Japan
Contacts
Public ContactMasato Naraoka
Hirosaki University Graduate School of Medicine Department of Neurosurgery
Outcome results
None listed